about
Color fluorescence ratio for detection of bronchial dysplasia and carcinoma in situ.Bronchoscopic treatment of patients with intraluminal microinvasive radiographically occult lung cancer not eligible for surgical resection: a follow-up study.Recombinant human interleukin-3 administered concomitantly with chemotherapy in patients with relapsed small cell lung cancer.Non-invasive stroke volume assessment in patients with pulmonary arterial hypertension: left-sided data mandatoryThe IASLC Lung Cancer Staging Project: data elements for the prospective project.Pemetrexed as a single agent in the therapy of advanced lung cancer.Unusual pulmonary lesions: case 2. Endobronchial carcinoid of the lung.Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis.What is early lung cancer? A review of the literature.Reflections on the 14th World Conference on Lung Cancer: A European PerspectiveCan quantifying free-circulating DNA in plasma be used to identify subjects with high-grade pre-invasive endobronchial lesions?Website visitors asking questions online to lung cancer specialists: what do they want to know?Direct costs associated with the disease management of patients with unresectable advanced non-small-cell lung cancer in The Netherlands.Influence of introduction of positron emission tomography on adherence to mediastinal staging protocols and performance of mediastinoscopy.Benefit of a second opinion: From metastatic disease to resectable lung cancer with sarcoid-like reaction.A de novo FLCN mutation in a patient with spontaneous pneumothorax and renal cancer; a clinical and molecular evaluation.DNA copy number alterations in endobronchial squamous metaplastic lesions predict lung cancer.Dual digital video-autofluorescence imaging for detection of pre-neoplastic lesions.EGFR mutation analysis in sputum of lung cancer patients: a multitechnique study.Elevated hTERT mRNA levels: A potential determinant of bronchial squamous cell carcinoma (in situ).Suprabasal p53 immunostaining in premalignant endobronchial lesions in combination with histology is associated with bronchial cancer.Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460.Side-effects of long-term administration of erlotinib in patients with non-small cell lung cancer.Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or first-line bosentan era.Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report.A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.Osteoblastic bone lesions developing during treatment with erlotinib indicate major response in patients with non-small cell lung cancer: a brief report.Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity.Cost-effectiveness of early intervention: comparison between intraluminal bronchoscopic treatment and surgical resection for T1N0 lung cancer patients.Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial.Ventilator-associated pneumothorax: drainage is not always necessary.Pulmonary vascular resistance and compliance stay inversely related during treatment of pulmonary hypertension.Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study.The performance of( 18)F-fluorodeoxyglucose positron emission tomography in small solitary pulmonary nodules.Progressive changes in right ventricular geometric shortening and long-term survival in pulmonary arterial hypertension.Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension.Clinically significant change in stroke volume in pulmonary hypertension.Predictors of mortality in inoperable chronic thromboembolic pulmonary hypertension.Primary lung cancer after treatment of head and neck cancer without lymph node metastasis: is there a role for autofluorescence bronchoscopy?Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
P50
Q30491011-B16DCCCB-1848-4C44-9C1E-A98E965BA5A2Q30720361-47BBDE1F-8089-499A-A7B7-295DBAD24558Q33345107-02053F6A-2572-43D8-B59B-EE6A12C1DB0BQ33382866-2737F0C6-4320-405A-BE71-8E3B14BB4B15Q33450260-3DEB50E2-D93A-401D-8476-337AAE03550AQ34649608-989A8628-3180-412E-9C82-4190615136B5Q34662504-A7F95886-789F-40C5-9680-381B9E207F3DQ34928738-0ACDF2F3-B9CC-41E4-9AAB-28B6BF147B37Q35859183-A93476EF-6E34-4072-AC40-DEEFA7EED9A4Q35863928-900209E1-C002-4C41-92F5-6B3CF1360BD4Q36919313-0CB2FD69-48C7-46BA-9DF7-F55B9B81BB41Q37092460-A90EED57-37F7-4A86-A9DE-EF44A1EE239DQ37274876-AFB2FC41-CB7C-4579-8C44-37982D741641Q37790981-49110B9B-9DB8-4579-A44E-DF1C137AA4AAQ38510308-7A37C5D7-F4F4-40DA-81C1-E60FE437CCE4Q39498677-BE26A973-DEEB-49E7-8EEC-E3CA7BDF97A9Q39723585-5BC3C7CB-46AA-41D5-906A-1FBE9D40CB2BQ39798848-BD08FD18-E900-47A0-B830-CD0BC964A8FCQ40129720-BE75E67A-23FB-469E-AFFE-2AB4D8016ACFQ40531792-34AD2C2F-DC65-4175-8785-97045324DDE7Q40592131-FDFF4C9B-ECB0-45F0-B52B-852CF790301FQ40751646-0EE85C31-53EF-453A-B15A-514BD3D26CE9Q42926981-09449DFE-AB77-4C7D-8EEA-C85AB4346423Q43004770-AED3E4EC-69B2-4714-BBEB-D044A1CB77A3Q43084814-71217C2B-3644-437C-A864-B7D6304DA0E0Q43098017-A1493D67-7BFF-4EF7-861B-82063A36A7C6Q43112783-3FC999C0-9936-4EC4-BDBB-A6C266BF8CBBQ43222276-03B2703E-F2B0-44D2-A64F-87B66CA9EFA6Q43806921-3D7798DC-F3CE-4B45-A8A6-CC97412B51FEQ43972336-D21F207F-F3A6-4E4A-A8C9-941E81BCF616Q44277075-95B34C63-59A8-49AC-BF37-2107732BE1F7Q44348768-1BCFF19B-A829-4F73-B386-D1F410068E4AQ44632420-C9A24AB1-7BB0-4CDD-9FBF-A0CC18669EA3Q44919921-994DCDCA-C14D-48BC-90AC-AA3D93562C6FQ44969578-D4116C03-C8E9-4E23-A5DC-7F163C85E090Q45198254-C48B72C1-15AB-478C-AE14-BBAE45B104B7Q45247025-CEDBC2EA-1DBC-4BB2-8B86-DE29D7BC0800Q45413899-D2578362-B246-4F56-8E8E-861F634E0BE6Q45896531-7A5F993E-7CB2-45E6-BB96-F3B132C5D7F0Q46215379-CD597CDC-1EEE-4552-A615-26CB7E0320BF
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Pieter E Postmus
@ast
Pieter E Postmus
@en
Pieter E Postmus
@es
Pieter E Postmus
@nl
type
label
Pieter E Postmus
@ast
Pieter E Postmus
@en
Pieter E Postmus
@es
Pieter E Postmus
@nl
prefLabel
Pieter E Postmus
@ast
Pieter E Postmus
@en
Pieter E Postmus
@es
Pieter E Postmus
@nl
P106
P31
P496
0000-0002-7774-2868